Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin inhalation - QDose

Drug Profile

Insulin inhalation - QDose

Alternative Names: Dry powder inhaled insulin - MicroDose/Vectura

Latest Information Update: 13 Feb 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QDose
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetes mellitus

Highest Development Phases

  • Suspended Diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
  • 11 Sep 2008 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top